This meta-analysis concluded that survival was longer in chemotherapy-naïve vs. chemotherapy-resistant patients, those with an ECOG PS of 0 vs. 1–2, those with only lymph node metastases vs. those with bone, lung, or liver metastases, those with normal vs. elevated serum alkaline phosphatase (ALP), those with higher vs. lower average standard uptake values (SUVaverage) and minimal SUV (SUVmin), those who received an intensified vs. conventional schedule of RLT, and those who had a PSA decline of at least 50% [31]. Here, KLK3 is linked to metastatic malignant neoplasm in the lymph nodes.